Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577414 | 0.94 | CHRM3 (0.48) | MEN1KMT2APOLBCHRM3KDM4E | |
| SCHEMBL5577724 | 0.91 | ACKR3 (0.50) | MEN1KMT2ASIGMAR1CHRM3ALDH1A1 | |
| SCHEMBL5577427 | 0.89 | ACKR3 (0.55) | KMT2APOLBCHRM3ALDH1A1DRD2 | |
| SCHEMBL5577288 | 0.89 | CHRM3 (0.56) | MEN1KMT2APOLBACHECHRM3 | |
| SCHEMBL5577658 | 0.89 | CHRM3 (0.47) | MEN1KMT2APOLBCHRM3ALDH1A1 | |
| SCHEMBL5577295 | 0.88 | SMN1; SMN2 (0.53) | MEN1KMT2APOLBBCHEACHE | |
| SCHEMBL5577685 | 0.88 | KMT2A (0.46) | MEN1KMT2APOLBCHRM3ALDH1A1 | |
| SCHEMBL5577332 | 0.86 | KMT2A (0.48) | MEN1KMT2APOLBBCHEACHE | |
| SCHEMBL5577672 | 0.85 | KMT2A (0.51) | MEN1KMT2APOLBSIGMAR1CHRM3 | |
| SCHEMBL5577541 | 0.84 | PTBP1 (0.50) | MEN1KMT2APOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MEN1 748/4885KMT2A 3527/4885POLB 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.